Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Taro Pharmaceutical Industries Ltd.    TARO   IL0010827181

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Taro Pharmaceutical Industries Ltd. : Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/08/2012 | 11:25pm CET

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") announced today that it delivered a letter to one of its shareholders IsZo Capital Management LP ("IsZo") in response to IsZo's letter to Taro's Special Committee of the Board of Directors dated November 5, 2012. The full text of the letter is set forth below:

Re: Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

Dear Mr. Sheehy,

We at Taro are very appreciative of our shareholders' communications. More recently, our ability to respond to certain inquiries has been limited in light of the pending merger between Taro and Sun Pharma and the related shareholder meeting scheduled December 6, 2012. Rather, our management team's primary focus continues to be on Taro's core business, the performance of which speaks for itself.

Without responding to your many unfounded allegations over the past few months, I feel compelled to publicly correct one of your most recent statements. In your November 5th letter and corresponding press release, you contend that Taro is "gaming its reserves." Your allegation is simply untrue and your comment is, at a minimum, irresponsible to your fellow Taro shareholders.

As a NYSE listed company, Taro takes its financial accounting and reporting obligations very seriously. Although our quarterly financial reporting is presented on an unaudited basis, the accounting methodologies used in estimating our reserves are "consistently applied" quarter to quarter, in conformity with U.S. GAAP. Over the last couple of years, at the request of our Board and Audit Committee, we have taken an extra step by having our independent auditors perform certain "agreed upon procedures" on our financial statements focusing on specific areas, including reserves, prior to issuing our quarterly releases, including that for the quarter ended September 30, 2012.

Given your broad industry knowledge, you undoubtedly appreciate that, while IMS data is useful to the industry for general U.S. market intelligence and a general understanding of long term, product trends, it is not reliable (or prepared) for consolidated financial reporting analysis as you propose.

Finally, I recognize your excitement for Taro as expressed in your letter. I believe that all Taro shareholders have benefited tremendously at what the new management team, under the leadership of Mr. Shanghvi and, subsequently, Mr. Sundaram, have accomplished since the change in control in September 2010.

Sincerely,

/s/ Jim Kedrowski

Jim Kedrowski
Interim Chief Executive Officer

************************

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.

Taro Pharmaceutical Industries Ltd.
William J. Coote, 914-345-9001
VP, Treasurer
William.Coote@taro.com


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TARO PHARMACEUTICAL INDUST
01/06 TARO PHARMACEUTICAL INDUSTRIES : Announces Sale of U.S. Rights to Keveyis® to St..
2016 TARO PHARMACEUTICAL INDUSTRIES : GPM Reminds Investors of the December 27th Dead..
2016 TARO PHARMACEUTICAL INDUSTRIES : Strongbridge Biopharma plc Announces Acquisitio..
2016 TARO 72 HOUR DEADLINE ALERT : Approximately 72 Hours Remain; Former Louisiana At..
2016 Levi & Korsinsky, LLP Reminds Shareholders of Taro Pharmaceutical Industries ..
2016 TARO PHARMACEUTICAL INDUSTRIES : Announces Sale of U.S. Rights to Keveyis® to St..
2016 DECEMBER 27 DEADLINE ALERT : Law Offices of Howard G. Smith Reminds Taro Pharmac..
2016 SHAREHOLDER REMINDER : Kessler Topaz Meltzer & Check, LLP Announces Deadline in ..
2016 TARO PHARMACEUTICAL INDUSTRIES : GPM Reminds Investors of the December 27th Dead..
2016 TARO PHARMACEUTICAL INDUSTRIES LTD. : SHAREHOLDER REMINDER: Deadline in Class Ac..
More news
Sector news : Pharmaceuticals - NEC
01:30pDJJOHNSON & JOHNSON : Revenue Rises But Forecast Disappoints
12:35a U.S. reaches settlement with Endo on pay-for-delay charges
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/20 Teva's Got Potential - And The Complexity To Go With It
01/20 Would You Buy Secretive Taro Pharmaceutical Based On The Track Record Of Indi..
2016 TEVA : Is It Cheap Enough?
2016 Strongbridge Biopharma acquires U.S. rights to KEVEYIS from Taro Pharmaceutic..
2016 GREENBLATT WIZARDRY : A Quantitative Look At The Magic Formula
Advertisement
Financials ($)
Sales 2017 902 M
EBIT 2017 550 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2017 9,18
P/E ratio 2018 10,06
Capi. / Sales 2017 4,59x
Capi. / Sales 2018 4,94x
Capitalization 4 144 M
More Financials
Chart TARO PHARMACEUTICAL INDUST
Duration : Period :
Taro Pharmaceutical Indust Technical Analysis Chart | TARO | IL0010827181 | 4-Traders
Full-screen chart
Technical analysis trends TARO PHARMACEUTIC...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 135 $
Spread / Average Target 34%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Abhay Gandhi Chief Executive Officer & Director
Dilip Shantilal Shanghvi Chairman
Itamar Karsenti Vice President & Operations Head-Haifa
Mariano Balaguer VP, Chief Financial & Accounting Officer
Avi Avramoff Global Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TARO PHARMACEUTICAL IN..-4.07%4 144
JOHNSON & JOHNSON-1.13%309 896
ROCHE HOLDING LTD.0.39%200 025
PFIZER INC.-3.14%190 910
NOVARTIS AG-4.32%183 809
MERCK & CO., INC.4.99%170 419
More Results